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Objectives: To identify the mechanism of in vivo development of carbapenem
resistance in Klebsiella pneumoniae.
Methods: Seven sequential isolates of K. pneumoniae were obtained from twin
infants with pneumonia. Antimicrobial susceptibility testing was performed by agar
dilution method. Carbapenemases including KPC and MβL were initially screened
using phenotypic methods, and carbapenemase-encoding genes were identified by
polymerase chain reaction and amplicon sequencing. Plasmids of all clinical isolates
and the conjugants of resistant isolates were estimated by S1 pulsed-field gel
electrophoresis (PFGE). Molecular typing were conducted by PFGE of XbaI-digested
genomic DNA and multilocus sequence typing.
Results: For old brother, the first and third isolates were susceptible to meropenem,
whereas the second and fourth isolates were resistant (MICs 16 mg/L). The first and
second isolates from the young brother were susceptible to meropenem whereas
the third isolate was resistant. All the resistant isolates produced NDM-1 metallo-
β-lactamase. PFGE of XbaI-digested DNA revealed almost identical patterns with
similarity indices of above 92% for all the seven isolates. All the isolates had the same
sequence type named sequence type 37 (ST37).
Conclusion: To our knowledge, this is the first documented case of development
of carbapenem resistance in vivo mediated by NDM-1 metallo-β-lactamase in
K. pneumoniae during treatment of pneumonia with meropenem.
Keywords: Klebsiella pneumoniae, NDM-1 metallo-β-lactamase, development of carbapenem resistance,
meropenem, in vivo
INTRODUCTION
For the ﬁrst time in its history, Centers for Disease Control and Prevention [CDCP] (2013)
categorized drug-resistant superbugs by threat level. Carbapenem-resistant Enterobacteriaceae
(CRE) strain makes CDC issue an “urgent threat” in 2012. It is well-known that infections due to
extensively drug-resistant CRE are associated with signiﬁcant morbidity and mortality, and such
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resistant strains have made their way to the most vulnerable
populations, including children (Lledo et al., 2009; Logan,
2012). Production of Klebsiella pneumoniae carbapenemase
(KPC) or metallo-β-lactamase (MβL) is the main mechanism of
carbapenem resistance in Enterobacteriaceae. Our previous study
reported (Chen et al., 2011) that 70.6% of 109 carbapenem-
resistant K. pneumoniae isolates produced KPC-2-type
carbapenemase, and GIM-1-type or VIM-1-type MβL was
detected in 9.2% of the isolates. Very few studies have ever
reported development of carbapenem resistance due to bla−KPC
or losing a porin in Escherichia coli or K. pneumoniae during
therapy (Hong et al., 2005; Elliott et al., 2006). Here, we report the
alternate isolation of carbapenem-susceptible and carbapenem-
resistant NDM-1 MβL-producing K. pneumoniae from twin
infants in a children’s hospital and in vivo development of
carbapenem resistance during carbapenem therapy. We have
obtained consent from the legal guardians to publish this case
study.
MATERIALS AND METHODS
Bacterial Strains
Seven sequential isolates of K. pneumoniae obtained from
twin infants in Shanghai Children’s Hospital, Shanghai, China,
were isolated from sputum. The strains were identiﬁed using
VITEK 2 Compact System (bioMérieux, France). E. coli ATCC
25922, Salmonella ser. Braenderup H9812 and E. coli J53
(sodium azide-resistant) were used as quality control strain
in antimicrobial susceptibility testing, reference marker in
pulsed-ﬁeld gel electrophoresis (PFGE) and recipient strain in
conjugation experiment, respectively. A well-characterized strain
of Citrobacter freundii 1641 (producing an IMP-9-type metallo-
beta-lactamase), K. pneumoniae 2528 (producing a KPC-2-type
carbapenemase), and K. pneumoniae 1789 were used as positive
controls for screening carbapenemase genes by polymerase chain
reaction (PCR), respectively.
Antimicrobial Susceptibility Testing
Antimicrobial susceptibility testing was performed using agar
dilution method for determination of minimum inhibitory
concentrations (MICs). The results were interpreted according
to Clinical Laboratory Standards Institute (CLSI) criteria
(Clinical and Laboratory Standards Institute [CLSI], 2014).
Carbapenemases including KPC and MβL were initially screened
using phenotypic methods such as Modiﬁed Hodge Test, and
combined disk test with 3′-aminophenylboronic acid (APB)
and/or EDTA.
Genotypic Detection of β-lactamase Genes
The presence of genes encoding the carbapenemases including
KPC, NDM-1, VIM, IMP, SPM, SME, GIM, BIC, SIM, AIM, and
DIM were investigated in all the seven clinical isolates by using
previously described primers (Qin et al., 2014). PCR amplicons
were sequenced and the DNA sequences obtained were compared
with those available in the NCBI GenBank database using BLAST
searches.
Transfer of Carbapenem Resistance
Transferability of carbapenem resistance was analyzed using
conjugation experiments in Luria-Bertani broth with sodium-
azide resistant E. coli J53 as the recipient, as described previously
(Zhang et al., 2011). Conjugants were selected onMueller-Hinton
agar supplemented with sodium-azide (150 mg/l) and ertapenem
(0.5 mg/l) to select for plasmid-encoded resistance. Plasmids of
all clinical isolates and the conjugants of resistant isolates were
estimated by S1 PFGE.
Clonal Relationships
Clonal relationships were analyzed using PFGE of XbaI-digested
genomic DNA and multilocus sequence typing (MLST). The
results of PFGE were interpreted according to the criteria
proposed by Tenover et al. (1995).
Clinical History Information
Clinical data were collected via chart review for each patient
from the hospital’s uniﬁed electronic database. The following
parameters were assessed: (1) general demographics, such as age,
sex, and other background information; (2) the ward where the
patient stayed; (3) use of antibiotics, particularly carbapenems,
and extended-spectrum cephalosporins; and (4) potential risk
factors for the occurrence and spread of CRKP (Carbapenem-
resistant K. pneumoniae). Infection or colonization with a CRKP
isolate was deﬁned according to CDC’s deﬁnition of nosocomial
infections (Garner et al., 1988).
RESULTS
Antimicrobial Susceptibility Testing
The conﬁrmation of MIC results showed that the ﬁrst and
third isolates from the old brother (Twin A), and the ﬁrst
and second isolates from the young brother (Twin B), were
susceptible to carbapenems, whereas the second and fourth
isolates from Twin A, and the third isolate from Twin B
were resistant to carbapenem (MIC 16 mg/L; Table 1). All
isolates were susceptible to polymyxin B, tigecycline, amikacin,
ciproﬂoxacin, but were broadly resistant to cephalosporins.
As expected, the carbapenem-resistant isolates were resistant
to β-lactam/β-lactam inhibitor combinations. The result of
phenotypic detection of carbapenemase indicated metallo-
β-lactamase production among carbapenem-resistant isolates,
and extended-spectrum β-lactamases (ESBLs) production in
carbapenem-susceptible isolates, respectively.
Genotypic Detection of β-lactamase
Genes
Polymerase chain reaction and DNA sequencing for
carbapenemases genes indicated that blaNDM−1 was present
in three carbapenem-resistant isolates. No PCR products were
obtained for any of the other carbapenemase genes investigated.
Transfer of Carbapenem Resistance
Carbapenem resistance was successfully transferred from all
the three carbapenem-resistant K. pneumoniae to E. coli J53.
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All conjugants exhibited signiﬁcantly reduced carbapenem
susceptibility to ertapenem (MICs 4 mg/L), and were consistent
with detection of blaNDM−1 in these conjugants. The plasmid
containing bla−NDM−1 is approximately 54 kb (Figure 1).
Clonal Relationships
Pulsed-ﬁeld gel electrophoresis of XbaI-digested DNA revealed
almost identical patterns with similarity indices of above 92%
for all the isolates. However, the PFGE pattern of carbapenem-
resistant isolates diﬀered from carbapenem-susceptible isolates
by more than one or two bands (Figure 2). Likewise, seven
isolates had the same sequence type named sequence type 37
(ST37).
Clinical History Information
The 7-days-old twin infants with acute respiratory distress
syndrome were admitted to the ICU in Children’s Hospital of
Shanghai. Cefotaxime (0.06 g q12 h) was used prophylactically.
(1) For Twin A, pneumonia was diagnosed on admission and
mechanical ventilation was provided. A meropenem-susceptible,
ESBL-producing K. pneumoniae isolate was cultured from
sputum specimen 17 days later. The antibiotic therapy was
tailored to meropenem 0.09 g per day intravenously, but a
meropenem-resistant, blaNDM−1-positive K. pneumoniae isolate
was cultured 6 days later. Then the meropenem regimen was
changed to meropenem (0.03 g q8 h) plus ampicillin/sulbactam
(0.1 g q8 h). About 6 days after discontinuation of meropenem
therapy, a third meropenem-susceptible, ESBL-producing
K. pneumoniae isolate was cultured from sputum specimen. The
antibiotic therapy of intravenous meropenem plus ampicillin-
sulbactam remained unchanged. The fourth isolate, cultured
from a sputum specimen about 17 days later, was found resistant
to meropenem. The regimen was modiﬁed to meropenem
(0.1 g q8 h) plus ampicillin/sulbactam (0.118 g q8 h). No
subsequent isolate of K. pneumoniae was isolated from
sputum, blood, cerebrospinal ﬂuid, central venous catheter
tip specimens, or tracheal aspirates any more. Meropenem
plus ampicillin/sulbactam was stopped 15 days later. The
patient recovered and was discharged from hospital on May
25, 2014. (2) For Twin B, subsequent shock and congenital
heart disease were identiﬁed ﬁrstly. Pneumonia was diagnosed
18 days later. The ﬁrst and second meropenem-susceptible,
ESBL-producing K. pneumoniae isolates were cultured from
sputum specimen 2 and 4 days later, respectively. The antibiotic
therapy was tailored to intravenous meropenem (0.07 g q8 h)
plus ampicillin/sulbactam (0.09 g q8 h). After meropenem
therapy was discontinued about 10 days later, a meropenem-
resistant, NDM-1 MβL-producing K. pneumoniae isolate was
cultured from a sputum specimen. The patient recovered and
was discharged from hospital on May 5, 2014.
DISCUSSION
The carbapenemase-producing Enterobacteriaceae isolates
carrying additional resistance genes to multiple antibiotic
classes have become resistant to nearly all available therapies.
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FIGURE 1 | Plasmid DNAs from Klebsiella pneumoniae strains (A) and Southern hybridization of plasmid DNAs with a bla−NDM−1 probe (B). Lane 1:
A1, Lane 2: A2, Lane 3: A2-conjugant, Lane 4: B2, Lane 5: B3, Lane 6: B3-conjugant.
FIGURE 2 | DNA fingerprinting of K. pneumoniae strains by PFGE. A1, A2, A3, and A4 isolated from twin A (old brother); B1, B2, and B3 isolated from twin B
(young brother).
Interestingly, the predominant carbapenemase types of CRE
isolates are diﬀerent between adults and children. For adults,
KPC is the primary carbapenemase whereas NDM-1 metallo-
β-lactamase is for children (Logan, 2012). Since the ﬁrst NDM-1
was identiﬁed in Kumarasamy et al. (2010) in India, NDM-
1-producing Enterobacteriaceae have been reported in many
countries. In China, the incidence of CRE isolates especially
K. pneumoniae increased rapidly (Hu et al., 2012). These results
suggest that the increasing prevalence of CRE in hospital or
environment may attribute to the failure to control the spread of
these strains (Walsh et al., 2011). As reported (Gasink et al., 2009;
Logan, 2012), the risk factors for acquiring CRE isolates among
hospitalized patients included prior use of broad-spectrum
antibiotics, mechanical ventilation, indwelling urinary catheters,
and change of sickbeds.
Unlike the risk factors of exogenous nosocomial acquired CRE
isolate, the endogenous isolate is usually relevant to the use of
broad-spectrum antibiotics, especially carbapenems. In this case,
resistance emerged unequivocally in the original strain during
meropenem therapy, because the ﬁndings of PFGE proﬁles and
MLST were almost identical with similarity indices of above
92% for all isolates. Compared with the resistant strains, the
susceptible isolates are lack of NDM-1 MβL, which is the major
mechanism mediating resistance to meropenem. Curiously, the
meropenem-susceptible and –resistant isolates were isolated
alternately from the old brother in relation to changing antibiotic
regimen. We speculated that the K. pneumoniae colonies
probably have become heterogeneous population. Either resistant
or susceptible variants may become dominant under speciﬁc
selective pressure of antibiotics.
For the young brother, we cannot exclude the possibility
that the ﬁnal meropenem-resistant, NDM-1 MβL producing
K. pneumoniae isolate was derived from the initial meropenem-
susceptible K. pneumoniae by developing carbapenem resistance
in vivo, but we consider this unlikely, because this ﬁnal isolate
was cultured about 8 days after meropenem therapy was stopped.
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It is more probable that the ﬁnal isolate was transferred
from the old brother via medical staﬀ, their parents or close
contact each other. Another possible explanation is that these
K. pneumoniae colonies probably exist heterogeneously. Our
study also showed that bla−NDM−1 genes located on plasmid
were readily transferable, which implies that the infections caused
by carbapenemase-producing Enterobacteriaceae isolates might
prove diﬃcult to control once they had emerged and rapidly
disseminated in clinical setting. Based on our experience, we
urge caution on strict infection control measures, including
more accurate detection, judicious use of carbapenems, and hand
hygiene for containing CRE strains and preventing nosocomial
transmission (Lledo et al., 2009; Qin et al., 2014).
To our knowledge, this is the ﬁrst documented case of
carbapenem resistance mediated by NDM-1 metallo-β-lactamase
emerging in K. pneumoniae during treatment of pneumonia
with meropenem. As very few novel antimicrobials have
been discovered for the treatment of infections due to CRE
isolates, the occurrence of a carbapenem-hydrolyzing enzyme
in Enterobacteriaceae is disturbing. The spread of CRE and
increasing use of carbapenems will make such resistant isolates
more prevalent in the world.
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